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artery FMD represents a largely nitric oxide-mediated, endothelium-
dependent dilation and is attenuated by preceding forearm IR. FMD 
is a well-validated model to study IR-injury in humans. Forearm 
ischemia was induced by inflating a blood pressure cuff around the 
upper arm level. FMD analysis was performed offline by investigators 
blinded to the treatment arm.
Results: Baseline FMD did not differ between metformin pretreat-
ment and no pretreatment (6.9% [3.6%] and 6.1% [3.5%], respec-
tively; P = 0.27). FMD was significantly lower after forearm IR in 
both treatment arms (4.4% [3.3%] and 4.3% [2.8%], respectively; 
P < 0.01 in both groups). A 2-way repeated measures ANOVA 
revealed that metformine treatment did not prevent the decrease in 
FMD by IR (P = 0.50).
Conclusion: In this study, we investigated for the first time whether 
treatment with metformin limits IR-injury in humans in vivo. In con-
trast with previous studies in animal models of myocardial infarction, 
we did not observe any protective effect of metformin on endothelial 
IR-injury, measured with brachial artery FMD, in healthy middle-
aged volunteers. Our study does not exclude that metformin has pro-
tective effects in patients with cardiovascular disease or patients with 
DM. As such, additional studies, including studies in these patient 
groups, are needed to explore the discrepancy between the previous 
preclinical findings and our current results.
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Introduction: Ticagrelor is a P2Y12 receptor antagonist, with supe-
rior effects but also ensuing enhanced bleeding risk compared with 
clopidogrel. Determination of platelet inhibition may be useful to 
confirm efficient platelet inhibition on an individual patient level and 
to identify patients at risk for bleeding, particularly in a preopera-
tive setting. The vasodilator-associated stimulated phosphoprotein 
(VASP) phosphorylation assay specifically measures platelet P2Y12 
inhibition but has so far required special flow cytometric equipment 
and individual sample processing. A new ELISA-based VASP assay 
has been developed that allows batch analysis after initial platelet 
activation. Due to the reversible binding of ticagrelor, it is unclear if 
the ELISA and flow cytometric assays provide comparable results.
Patients (or Materials) and Methods: We hypothesized that the con-
ventional and new methods may be comparable when the revers-
ible P2Y12 inhibitor ticagrelor is used. We pair-wise compared the 
platelet reactivity index (PRI) between assays in a prospective clinical 
trial. Healthy volunteers received a single 180-mg loading dose of 
ticagrelor.
Results: PRI-values of the 2 methods correlated well (r = 0.97, P < 
0.001). Ticagrelor rapidly decreased PRI values on average after 50 
minutes, but nadir levels 2 to 6 hours after ticagrelor intake were 
15% higher when PRI% was measured with the flow cytometric 
method. Bland-Altman analysis showed that the flow cytometric 
assay measured markedly higher PRI levels than the new ELISA-
based technique (mean difference, 13%).
Conclusion: The new ELISA-based VASP assay offers an alternative 
to the currently used flow cytometric method, but measures lower 
PRI levels, particularly when PRI falls below 20% after ticagrelor 
intake.
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Introduction: Primary aldosteronism (PA) is the most prevalent form 
of endocrine hypertension, due to autonomous aldosterone produc-
tion. The 2 main causes of PA are aldosterone-producing adenome 
(APA) and bilateral adrenal hyperplasia (BAH). Aldosterone, syn-
thesized and secreted by the zona glomerulosa (ZG) of the adrenal 
gland, is physiologically regulated by angiotensin II (AngII), plasma 
potassium concentration [K+], and ACTH. However ,the molecu-
lar mechanisms that lead to the aldosterone hyperproduction are 
not completely understood. Recent studies have show the presence 
of somatic mutations of the inwardly rectifying potassium channel 
(KCNJ5) gene in APA, coding for the K+ channel KCNJ5. These 
mutations lie near or within the selectivity filter of the Kir3.4 channel, 
changing the normal Na+/K+ permability of the channel. Mutation-
scanning studies conducted on an Australian cohort with PA has 
identified germline single nucleotide polymorphisms (SNP) in the 
KCNJ5 gene (Q282E, E246K, and G247R) that may be relevant to 
the pathophysiology of PA in these subjects. However, the functional-
ity of these SNPs is unknown, so we have tested this directly.
Patients (or Materials) and Methods: The electrophysiology of these 
mutants was studied by applying a 2-electrode voltage clamp tech-
nique to Xenopus oocytes expressing the mutant KCNJ5 channels. A 
human H295R adrenocortical cell line was used as the experimental 
model to study the effects of the mutations on aldosterone release. 
Cells were transiently transfected with the WT KCNJ5 or mutant 
forms, and the aldosterone release was evaluated using a radioim-
munoassay, both under normal conditions and after depolarization 
with high extracellular K+ and Ang II.
Results: The Q282E and E246K KCNJ5 showed change in the selec-
tivity of the channel, with Na+ currents being observed in both of 
them. However, the G247R KCNJ5 behaved like the WT KCNJ5 
channel. Differences were also observed in the levels of aldosterone 
release from H295R cells expressing the different mutations, the 
details of which will be presented in the poster.
Conclusion: The findings from this work suggest that SNPs and 
rare variants outside the selectivity filter of KCNJ5 are functionally 
important and may be have a role in the autonomous aldosterone 
release in subjects with PA.
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Introduction: Hypoglycemic activity is one of the most important 
features of insulin derivatives and can be examined both in vitro and 
in vivo. The aim of the study was to evaluate activity of a new long-
acting insulin analogue using 3 different test systems.
